Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462264 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL31482354 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29605097 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL31188758 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL7414784 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL8769697 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL30823596 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL9935617 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29181630 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL6312855 | 0.75 | MAPT (0.54) | MAPTGAARAB9ASMN1; SMN2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-112601749-B | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2024039886-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-112409363-B | Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | 艾吉因生物股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-116640143-A | Benzodiazepine derivatives, compositions and methods for treating cognitive impairment | 艾吉因生物股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-3555100-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-4265889-A | DOPAMINERGIC, HYPOTENSIVE | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| US-4255422-A | DIURETICS, TREATMENT OF CARDIOVASCULAR DISORDERS | SMITHKLINE CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4197297-A | 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
| EP-0004794-A2 | Substituted benzazepines, processes for preparing them and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4171359-A | DOPAMINERGIC ACTIVITY | SMITHKLINE CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
| US-4165372-A | 6-Carboxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds and use as dopaminergic agents | SMITHKLINE CORPORATION (US) | 1979-08-21 | — | — | US | disclosed |
| US-4160765-A | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds | SMITHKLINE CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| EP-0002327-A1 | Pharmacologically active 6-lower alkyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, method of preparing them and intermediates | SMITHKLINE BECKMAN CORPORATION (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4052506-A | BENZAZEPINES | SMITHKLINE CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4011319-A | STIMULATING DOPAMINE RECEPTORS, RENAL VASODILATORS, DIURETICS | SMITHKLINE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | MAPT 69/4885GAA 1362/4885RAB9A 380/4885 |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | MAPT 60/4885GAA 1960/4885RAB9A 646/4885 |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | MAPT 70/4885GAA 1895/4885RAB9A 732/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | MAPT 70/4885GAA 1206/4885RAB9A 287/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | MAPT 77/4885GAA 1663/4885RAB9A 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.